A phase I trial evaluating the safety and immunogenicity of a candidate tuberculosis vaccination regimen, ChAdOx1 85A prime – MVA85A boost in healthy UK adults
Open Access
- 15 November 2019
- journal article
- research article
- Published by Elsevier
- Vol. 38 (4) , 779-789
- https://doi.org/10.1016/j.vaccine.2019.10.102
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- Pre-existing immunity against vaccine vectors – friend or foe?Microbiology, 2013
- A Novel Chimpanzee Adenovirus Vector with Low Human Seroprevalence: Improved Systems for Vector Derivation and Comparative ImmunogenicityPLOS ONE, 2012
- Phase Ia Clinical Evaluation of the Safety and Immunogenicity of the Plasmodium falciparum Blood-Stage Antigen AMA1 in ChAd63 and MVA Vaccine VectorsPLOS ONE, 2012
- How tumour necrosis factor blockers interfere with tuberculosis immunityClinical and Experimental Immunology, 2010
- Regulatory T Cells Modulate Th17 Responses in Patients with Positive Tuberculin Skin Test ResultsThe Journal of Infectious Diseases, 2010
- A Critical Role for CD8 T Cells in a Nonhuman Primate Model of TuberculosisPLoS Pathogens, 2009
- Immunisation with BCG and recombinant MVA85A induces long‐lasting, polyfunctional Mycobacterium tuberculosis‐specific CD4+ memory T lymphocyte populationsEuropean Journal of Immunology, 2007
- Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania majorNature Medicine, 2007
- Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectivenessThe Lancet, 2006
- Interleukin-2: Inception, Impact, and ImplicationsScience, 1988